Pfizer Inc. (PFE) Q2 FY2026 8-K Filings and Company Events

Filings that contain financial statements

• 8-K dated August 4, 2026 (accession 0000078003-26-000094), Exhibit 99, second-quarter and first-six-months 2026 unaudited condensed consolidated statements of operations, revenue-by-product tables, and GAAP-to-Adjusted reconciliations.
• 8-K dated May 5, 2026 (accession 0000078003-26-000053), Exhibit 99, first-quarter 2026 unaudited condensed consolidated statements of operations, revenue-by-product tables, and GAAP-to-Adjusted reconciliations.
• 8-K dated February 3, 2026 (accession 0000078003-26-000005), Exhibit 99, fourth-quarter and full-year 2025 unaudited condensed consolidated statements of operations, revenue-by-product tables, and GAAP-to-Adjusted reconciliations.
• 8-K dated November 4, 2025 (accession 0000078003-25-000149), Exhibit 99, third-quarter and first-nine-months 2025 unaudited condensed consolidated statements of operations, revenue-by-product tables, and GAAP-to-Adjusted reconciliations.
• 8-K dated August 5, 2025 (accession 0000078003-25-000136), Exhibit 99, second-quarter and first-six-months 2025 unaudited condensed consolidated statements of operations, revenue-by-product tables, and GAAP-to-Adjusted reconciliations.
• 8-K dated April 29, 2025 (accession 0000078003-25-000111), Exhibit 99, first-quarter 2025 unaudited condensed consolidated statements of operations, revenue-by-product tables, and GAAP-to-Adjusted reconciliations.
• 8-K dated February 4, 2025 (accession 0000078003-25-000017), Exhibit 99, fourth-quarter and full-year 2024 unaudited condensed consolidated statements of operations, revenue-by-product tables, and GAAP-to-Adjusted reconciliations.

Earnings and guidance

August 4, 2026, Second-quarter 2026 results (8-K, accession 0000078003-26-000094). Revenues of $15.0 billion, up 3% (1% operationally). Reported loss per share of $(0.04) versus reported EPS of $0.51 a year earlier, driven by $4.3 billion of non-cash intangible-asset impairments (including a $3.8 billion IPR&D impairment tied to unfavorable sigvotatug vedotin trial results and a $525 million Oxbryta developed-technology impairment after Pfizer concluded there was no viable pathway to return the product to the U.S. market). Adjusted diluted EPS was $0.77, roughly flat year over year. Pfizer raised full-year 2026 revenue guidance by $500 million at the midpoint to $60.5–$62.5 billion (from $59.5–$62.5 billion) and reaffirmed Adjusted diluted EPS guidance of $2.80–$3.00, which now absorbs an approximately $0.10 per-share charge tied to the Innovent Biologics licensing transaction that closed July 10, 2026. Pfizer also announced additional productivity-savings initiatives: roughly $1.0 billion of added net cost savings under its cost-realignment program (bringing the cumulative target to about $6.7 billion through 2029) and a new phase of its Manufacturing Optimization Program targeting roughly $1.5 billion of additional savings through 2029.

May 5, 2026, First-quarter 2026 results (8-K, accession 0000078003-26-000053). Revenues of $14.5 billion, up 5% (2% operationally). Reported diluted EPS of $0.47 versus $0.52 a year earlier; Adjusted diluted EPS of $0.75 versus $0.92. Pfizer reaffirmed all components of full-year 2026 guidance, including revenue of $59.5–$62.5 billion and Adjusted diluted EPS of $2.80–$3.00.

February 3, 2026, Fourth-quarter and full-year 2025 results (8-K, accession 0000078003-26-000005). Full-year 2025 revenues of $62.6 billion (down 2% operationally); full-year reported diluted EPS of $1.36 and Adjusted diluted EPS of $3.22. Fourth-quarter 2025 revenues of $17.6 billion; reported diluted loss per share of $(0.29), reflecting $4.4 billion of intangible-asset impairment charges (primarily $1.6 billion for disitamab vedotin, $820 million for Tukysa, and $820 million for osivelotor); Adjusted diluted EPS of $0.66. Pfizer reaffirmed the full-year 2026 guidance it had issued on December 16, 2025 (revenue $59.5–$62.5 billion; Adjusted diluted EPS $2.80–$3.00).

December 16, 2025, Full-year 2026 guidance issued; 2025 revenue guidance revised (8-K, accession 0000078003-25-000167). Pfizer issued initial full-year 2026 guidance (revenue $59.5–$62.5 billion; Adjusted diluted EPS $2.80–$3.00) and narrowed/revised full-year 2025 revenue guidance to approximately $62.0 billion (from $61.0–$64.0 billion previously) while reaffirming other 2025 guidance components.

November 4, 2025, Third-quarter 2025 results (8-K, accession 0000078003-25-000149). Revenues of $16.7 billion, down 6% (7% operationally), driven by declining COVID-19 product sales; non-COVID portfolio grew 4% operationally. Reported diluted EPS of $0.62; Adjusted diluted EPS of $0.87. Pfizer reaffirmed full-year 2025 revenue guidance ($61.0–$64.0 billion) and raised and narrowed Adjusted diluted EPS guidance to $3.00–$3.15 (from $2.90–$3.10 previously); per the release, the updated guidance "takes into consideration our solid year-to-date performance, continued confidence in our business, progress with ongoing cost improvement initiatives, and improvement in our effective tax rate," and it includes (i.e., already absorbs) a one-time $1.35 billion Acquired IPR&D charge related to the in-licensing agreement with 3SBio, Inc., recorded in the third quarter of 2025 with an unfavorable impact of approximately $0.20 per share.

August 5, 2025, Second-quarter 2025 results (8-K, accession 0000078003-25-000136). Revenues of $14.7 billion, up 10% operationally. Reported diluted EPS of $0.51 versus $0.01 a year earlier; Adjusted diluted EPS of $0.78 versus $0.60. Pfizer reaffirmed full-year 2025 revenue guidance ($61.0–$64.0 billion) and raised Adjusted diluted EPS guidance by $0.10 at the midpoint to $2.90–$3.10, which the release states already absorbs a one-time impact of approximately $0.20 per share related to the 3SBio transaction, whose completion Pfizer announced in July 2025 (with the associated $1.35 billion Acquired IPR&D charge to be recorded in the third quarter of 2025).

February 4, 2025, Fourth-quarter and full-year 2024 results (8-K, accession 0000078003-25-000017). Full-year 2024 revenues of $63.6 billion, up 7% operationally; full-year reported diluted EPS of $1.41 and Adjusted diluted EPS of $3.11. Fourth-quarter 2024 revenues of $17.8 billion, up 21% operationally; reported diluted EPS of $0.07 and Adjusted diluted EPS of $0.63. Pfizer reaffirmed all components of full-year 2025 financial guidance provided on December 17, 2024, including revenue of $61.0–$64.0 billion and Adjusted diluted EPS of $2.80–$3.00.

Mergers, acquisitions and licensing

November 13, 2025, Completed acquisition of Metsera, Inc. (8-K, accession 0000078003-25-000159). Pfizer completed its previously announced acquisition of Metsera, a clinical-stage obesity/cardiometabolic biopharmaceutical company. Under the amended merger agreement (as amended November 7, 2025), Metsera shareholders received $65.60 per share in cash at closing, an enterprise value of approximately $7.0 billion, plus a non-transferable contingent value right of up to $20.65 per share tied to three clinical/regulatory milestones for Metsera's GLP-1/amylin combination programs. The original agreement (September 21, 2025) had valued the deal at $47.50 per share (~$4.9 billion enterprise value); the price was raised amid a competing proposal from Novo Nordisk, which Pfizer contested in Delaware courts before the deal closed on the raised terms.

July 10, 2026, Innovent Biologics licensing and collaboration agreement closed (disclosed in the August 4, 2026 earnings release, accession 0000078003-26-000094). Pfizer and Innovent Biologics entered a global licensing and collaboration agreement covering 12 early-stage oncology programs (antibody-drug conjugates and multi-specific antibodies). Innovent received a $650 million upfront payment and is eligible for up to $9.85 billion in milestone payments plus royalties; the transaction closed July 10, 2026, with an approximately $650 million Acquired IPR&D charge and roughly $0.10 per-share EPS impact expected in the third quarter of 2026.

December 2025, YaoPharma in-licensing agreement. Pfizer announced an exclusive global collaboration and in-license agreement with YaoPharma for YP05002, a Phase 1 oral GLP-1 receptor agonist for chronic weight management, for a $150 million upfront payment plus up to $1.935 billion in milestones and tiered royalties (disclosed in the February 3, 2026 earnings release, accession 0000078003-26-000005).

Management changes

June 18, 2026, Chief Financial Officer transition (8-K, accession 0000078003-26-000085). Dave Denton notified Pfizer he would step down as CFO effective August 15, 2026, for an opportunity outside the pharmaceutical industry; the company stated the departure was not related to Pfizer's financial or operating results or any disagreement over financial, operational, accounting or reporting matters. Cecile Guegan, previously Senior Vice President, Finance for the Global Biopharmaceutical Business, was named Interim CFO effective August 16, 2026, while Pfizer conducts an internal and external search for a permanent successor. A same-day 8-K (accession 0000078003-26-000087) confirmed Pfizer was reaffirming all components of its full-year 2026 financial guidance following the announcement.

Capital markets and capital allocation

November 18–21, 2025, Senior notes offering (8-K, accession 0001193125-25-291406). Pfizer completed a U.S. dollar-denominated public offering totaling roughly $6.0 billion aggregate principal across seven tranches: Floating Rate Notes due 2027 ($500 million), 3.875% Notes due 2027 ($1.0 billion), 4.200% Notes due 2030 ($1.0 billion), 4.500% Notes due 2032 ($1.25 billion), 4.875% Notes due 2035 ($1.25 billion), 5.600% Notes due 2055 ($500 million) and 5.700% Notes due 2065 ($500 million).

May 14–19, 2025, Euro-denominated notes offering (8-K, accession 0001193125-25-122480). Pfizer Netherlands International Finance B.V., a wholly owned Pfizer subsidiary, completed a euro-denominated offering totaling roughly €3.3 billion across four tranches: 2.875% Notes due 2029 (€750 million), 3.250% Notes due 2032 (€1.0 billion), 3.875% Notes due 2037 (€750 million) and 4.250% Notes due 2045 (€800 million), fully and unconditionally guaranteed by Pfizer Inc.

Capital deployment (per quarterly earnings releases). Pfizer has not repurchased any shares in 2025 or through the first half of 2026; its remaining share-repurchase authorization stood at $3.3 billion as of August 4, 2026, and current guidance does not anticipate buybacks in 2026. Full-year 2025 capital deployment included approximately $10.4 billion of internal R&D investment and approximately $8.8 billion of business-development spending (primarily the Metsera acquisition and the 3SBio in-licensing deal), alongside $9.8 billion of cash dividends ($1.72 per share). First-half 2026 deployment included $5.3 billion of internal R&D investment and $4.9 billion of cash dividends ($0.86 per share).

March 2026, ViiV Healthcare exit. Pfizer completed the exit of its 11.7% investment in ViiV Healthcare Limited, receiving $1.875 billion in proceeds (approximately $1.65 billion net of taxes and fees); the transaction, including a related $1.870 billion net gain, was recorded in the second quarter of 2026 (disclosed in the May 5, 2026 and August 4, 2026 earnings releases).

Restructuring and cost programs

April 29, 2025, Cost-realignment program expansion (8-K, accession 0000078003-25-000111). Pfizer announced approximately $1.2 billion of additional anticipated savings under its "Realigning Our Cost Base Program," expected by the end of 2027, with roughly $1.6 billion of one-time implementation costs. Combined with prior targets, Pfizer expected total net cost savings of approximately $5.7 billion through 2027. Pfizer separately identified about $500 million of additional R&D-organization savings, to be reinvested in R&D programs, with about $600 million of related one-time implementation costs through 2026. Subsequent earnings releases (November 2025, February 2026, August 2026) layered on further phases, most recently an additional $1.0 billion of net savings under the cost-realignment program (bringing the cumulative target to about $6.7 billion through 2029) and a new $1.5 billion Manufacturing Optimization Program phase, both announced with the August 4, 2026 results.

Governance

Annual shareholder meetings (8-K, accessions 0000078003-25-000109 and 0000078003-26-000044). At the April 24, 2025 and April 23, 2026 annual meetings, shareholders re-elected all director nominees, ratified KPMG LLP as independent auditor, and approved executive compensation on an advisory basis. At the 2026 meeting shareholders also approved an amendment to the 2019 Stock Plan; a shareholder proposal to adopt an independent board chair policy was not approved. At the 2025 meeting, shareholder proposals on golden-parachute votes and a religious-discrimination risk report were not approved.

Note on coverage

No SEC filing in this record discloses a resolution to Pfizer's litigation against Metsera, Novo Nordisk A/S and related parties over the competing acquisition proposal for Metsera (filed October–November 2025); the dispute appears to have been resolved by Pfizer's amended, higher-priced offer that closed on November 13, 2025, but no filing describes a settlement or court ruling.